Our Pricing

When Does Wegovy Begin Working? Starter Dose Guide

Understanding when does Wegovy start working UK timelines helps set realistic expectations during your weight loss journey. Most patients notice appetite suppression within the first 2-4 weeks of starting the 0.25mg starter dose, with measurable weight loss typically appearing by weeks 4-8 as doses gradually increase [1]. At Cured Pharmacy, our UK prescribers guide you through the complete dose escalation schedule, ensuring safe and effective treatment from your first injection.

When Does Wegovy Start Working: Expected Timeline

Wegovy (semaglutide 2.4mg) doesn't produce instant results — the medication builds gradually in your system through a carefully structured dose escalation protocol. Clinical data from the STEP trials shows that patients typically experience initial appetite changes within 1-2 weeks of their first 0.25mg injection, though visible weight loss usually becomes apparent between weeks 4-8 [1].

The starter dose of 0.25mg is deliberately low to allow your body to adjust to semaglutide's effects on gastric emptying and appetite regulation. This sub-therapeutic dose primarily serves to minimise gastrointestinal side effects rather than produce significant weight loss [2]. Most patients report feeling fuller sooner at mealtimes and experiencing reduced food cravings during this initial month.

By week 12, when you reach the 1mg dose, average weight loss in clinical trials was approximately 5-7% of baseline body weight [1]. The full therapeutic effect emerges once you reach the maintenance dose of 2.4mg at week 17, with peak weight loss typically occurring between months 12-16 of continuous treatment.

Wegovy Starter Dose Schedule UK

The UK-licensed Wegovy dosing schedule follows a precise 5-month escalation protocol approved by the MHRA. This gradual increase allows your gastrointestinal system to adapt whilst building therapeutic semaglutide levels in your bloodstream [2].

Each dose is maintained for exactly 4 weeks before progression. Your UK prescriber may recommend staying at a lower dose longer if you experience persistent nausea, vomiting, or diarrhoea — tolerability always takes priority over speed of escalation. Never increase your dose without clinical approval, as skipping steps significantly raises the risk of severe gastrointestinal adverse effects.

UK Dose Escalation Protocol

Weeks 1-4: 0.25mg once weekly (starter dose) — Weeks 5-8: 0.5mg once weekly — Weeks 9-12: 1mg once weekly — Weeks 13-16: 1.7mg once weekly — Week 17 onwards: 2.4mg once weekly (maintenance dose). Each injection is administered subcutaneously in the abdomen, thigh, or upper arm on the same day each week. If you miss a dose by more than 5 days, contact your prescriber before your next injection, as you may need to restart at a lower dose to avoid side effects [3].

What to Expect During the First Month on Wegovy

The first 4 weeks on the 0.25mg starter dose establish your body's tolerance to semaglutide. Approximately 60-70% of patients report mild nausea during this period, typically lasting 2-3 days after each weekly injection [2]. This usually diminishes significantly by week 3 as your system adapts.

Appetite suppression often appears before the scale moves. You may notice feeling satisfied with smaller portions, reduced interest in snacking between meals, and diminished cravings for high-fat or high-sugar foods. These changes reflect semaglutide's action on GLP-1 receptors in your brain's appetite control centres [1].

Average weight loss during the first month ranges from 1-3% of baseline body weight — modest but clinically significant. Some patients lose more, others less, depending on baseline BMI, adherence to dietary modifications, and individual metabolic response. The starter dose is not designed for maximum weight loss; it's preparing your body for higher therapeutic doses ahead.

Managing Early Side Effects

Mild gastrointestinal symptoms are common but manageable. Eat smaller, more frequent meals rather than three large ones. Avoid high-fat, greasy, or spicy foods that slow gastric emptying further. Stay well-hydrated, particularly if you experience any vomiting or diarrhoea. If nausea persists beyond the first week after each injection, speak with your UK prescriber — anti-emetic medication or temporarily pausing dose escalation may be appropriate [3].

How Long Until Wegovy Reaches Full Effectiveness

Wegovy achieves steady-state plasma concentration approximately 4-5 weeks after reaching each new dose level. This means the 2.4mg maintenance dose reaches its full pharmacological effect around week 21-22 of treatment [2]. However, weight loss continues to progress well beyond this point.

In the landmark STEP 1 trial, participants reached their maximum average weight loss of 14.9% at week 68 — nearly 16 months after starting treatment [1]. Weight loss velocity is highest between months 3-8, then gradually plateaus as you approach your individual set point. Approximately 85% of total weight loss occurs within the first 12 months.

It's crucial to understand that Wegovy is not a short-term intervention. Clinical trials demonstrate that discontinuing semaglutide typically results in gradual weight regain, with patients regaining approximately two-thirds of lost weight within 12 months of stopping [4]. The medication works by altering appetite signalling and metabolic regulation — effects that reverse when treatment ends.

Factors That Influence When Wegovy Starts Working

Individual response to semaglutide varies considerably based on several physiological and behavioural factors. Baseline BMI plays a significant role — patients with higher starting BMIs often see more rapid initial weight loss in absolute terms, though percentage reductions may be similar [1].

Adherence to lifestyle modifications significantly impacts outcomes. Wegovy is most effective when combined with a reduced-calorie diet and increased physical activity. Patients who maintain a 500-750 calorie daily deficit alongside semaglutide lose approximately 30% more weight than those relying on medication alone [2]. The drug reduces hunger and cravings, making dietary adherence easier, but it doesn't eliminate the need for behaviour change.

Metabolic factors also matter. Patients with insulin resistance, polycystic ovary syndrome, or hypothyroidism may experience slower initial weight loss, though long-term outcomes remain positive with appropriate management of underlying conditions. Your UK prescriber will assess these factors during your clinical consultation to set realistic expectations for your individual timeline.

Optimising Your Response to Wegovy

Consistency is paramount — inject on the same day each week to maintain stable semaglutide levels. Prioritise protein intake (1.2-1.6g per kg of ideal body weight daily) to preserve lean muscle mass during weight loss. Incorporate resistance training 2-3 times weekly alongside cardiovascular exercise. Track your progress through measurements and photos rather than daily weigh-ins, as weight fluctuates naturally. Most importantly, maintain realistic expectations: healthy, sustainable weight loss averages 0.5-1kg per week once you reach therapeutic doses [3].

Wegovy vs Other Weight Loss Treatments: Comparative Timeline

Compared to other prescription weight loss medications available in the UK, Wegovy demonstrates superior efficacy but requires patience during the escalation phase. Orlistat, a lipase inhibitor, produces modest weight loss (3-5% on average) that plateaus within 6 months [4]. Patients typically notice Orlistat's effects within 2-4 weeks, but the magnitude of weight loss is significantly lower than semaglutide-based treatments.

Saxenda (liraglutide 3mg) follows a shorter escalation schedule, reaching the maintenance dose in just 5 weeks. However, it requires daily injections and produces average weight loss of 8-9% — approximately 40% less than Wegovy's 14.9% average [1]. The more convenient once-weekly dosing and superior efficacy make Wegovy the preferred GLP-1 option for most patients, despite the longer time to full effectiveness.

Newer dual-agonist treatments like Mounjaro (tirzepatide) show even greater weight loss potential, with average reductions of 15-22.5% depending on dose [4]. However, Mounjaro is currently only licensed in the UK for type 2 diabetes, not obesity. For patients seeking prescription weight loss medication, Wegovy remains the gold-standard treatment with the most robust clinical evidence for long-term efficacy and safety.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
3. Novo Nordisk. (2023). Wegovy (semaglutide) 2.4mg Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss outcomes depend on multiple factors including baseline BMI, adherence to lifestyle modifications, and individual metabolic response.